Enhancement by pyrazolones of colistin efficacy against mcr-1-expressing E. coli: an in silico and in vitro investigation
- 24 July 2023
- journal article
- research article
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 37 (10) , 479-489
Abstract
Owing to the emergence of antibiotic resistance, the polymyxin colistin has been recently revived to treat acute, multidrug-resistant Gram-negative bacterial infections. Positively charged colistin binds to negatively charged lipids and damages the outer membrane of Gram-negative bacteria. However, the MCR-1 protein, encoded by the mobile colistin resistance (mcr) gene, is involved in bacterial colistin resistance by catalysing phosphoethanolamine (PEA) transfer onto lipid A, neutralising its negative charge, and thereby reducing its interaction with colistin. Our preliminary results showed that treatment with a reference pyrazolone compound significantly reduced colistin minimal inhibitory concentrations in Escherichia coli expressing mcr-1 mediated colistin resistance (Hanpaibool et al. in ACS Omega, 2023). A docking-MD combination was used in an ensemble-based docking approach to identify further pyrazolone compounds as candidate MCR-1 inhibitors. Docking simulations revealed that 13/28 of the pyrazolone compounds tested are predicted to have lower binding free energies than the reference compound. Four of these were chosen for in vitro testing, with the results demonstrating that all the compounds tested could lower colistin MICs in an E. coli strain carrying the mcr-1 gene. Docking of pyrazolones into the MCR-1 active site reveals residues that are implicated in ligand–protein interactions, particularly E246, T285, H395, H466, and H478, which are located in the MCR-1 active site and which participate in interactions with MCR-1 in ≥ 8/10 of the lowest energy complexes. This study establishes pyrazolone-induced colistin susceptibility in E. coli carrying the mcr-1 gene, providing a method for the development of novel treatments against colistin-resistant bacteria.Keywords
Funding Information
- Ratchadaphiseksomphot Endowment Fund (GCUGR1125623025D, GCUGR1125623025D)
- U.K. Engineering and Physical Sciences (EPSRC EP/M027546/1 (BristolBridge) and EP/M022609/1)
- U.K. Engineering and Physical Sciences and Medical (MRC MR/P007295/1)
This publication has 50 references indexed in Scilit:
- A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small MoleculesChemMedChem, 2016
- Resazurin-based 96-well plate microdilution method for the determination of minimum inhibitory concentration of biosurfactantsBiotechnology Letters, 2016
- Antimicrobial resistance: a global multifaceted phenomenonPathogens and Global Health, 2015
- Colistin for lung infection: an updateJournal of Intensive Care, 2015
- AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc MetalloproteinsJournal of Chemical Information and Modeling, 2014
- Taking into Account the Ion-Induced Dipole Interaction in the Nonbonded Model of IonsJournal of Chemical Theory and Computation, 2013
- LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug DiscoveryJournal of Chemical Information and Modeling, 2011
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- Lead- and drug-like compounds: the rule-of-five revolutionDrug Discovery Today: Technologies, 2004